Tokyo, July 12, 2006 (JCN) - Shionogi has obtained positive results from its current phase IIa trial of S-2367, its proprietary investigational agent for the treatment of obesity. S-2367 is a small molecule, oral, once-daily neuropeptide Y (NPY) Y5 receptor antagonist discovered by Shionogi Research Laboratories. NPY is an orexigenic neurotransmitter involved in appetite, energy intake, and energy consumption.
